Novoic is an AI-enabled software company focused on earlier detection of Alzheimer's disease using speech-based cognitive testing. Their technology detects subtle cognitive impairment and Alzheimer's neuropathology based on how people speak, enabling earlier diagnosis in just 10 minutes.

Novoic's mission is to scale access to early detection of Alzheimer's, supporting underserved communities at over 50 medical centers. Their speech-based tests are usable on any smart device without additional hardware and include features such as built-in quality control and automated speech recognition for high data integrity.

The company runs clinical trials and develops proprietary large audio and language AI models to improve the accuracy and robustness of their diagnostic algorithms, aiming for predictive, equitable, and bias-minimized results. Novoic emphasizes compliance with privacy, security (HIPAA/GDPR), and high-quality software development practices.

Key offerings include the Novoic Storyteller for automated speech assessment, a Dashboard for managing patient screening and monitoring at scale, and a Speech API for integrating speech biomarker technology into other platforms.

Novoic's software serves research and clinical trials, helping institutions find early-stage Alzheimer's patients faster and more reliably.

Contact can be made via email at [email protected]. More information and updates are available on their blog at https://blog.novoic.com.